---
figid: PMC11015836__OTT-17-307-g0003
figtitle: MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib
  and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation
  and BRAF V600E
organisms:
- NA
organisms_ner:
- Danio rerio
pmcid: PMC11015836
filename: OTT-17-307-g0003.jpg
figlink: /pmc/articles/PMC11015836/figure/f0003/
number: F3
caption: Schematic representation of Ras/RAF/MEK/ERK signaling pathway activation
  or inhibition at different stages of treatment in our case.
papertitle: MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib
  and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation
  and BRAF V600E.
reftext: Xiang Tan, et al. Onco Targets Ther. 2024;17:307-312.
year: '2024'
doi: 10.2147/OTT.S454902
journal_title: OncoTargets and Therapy
journal_nlm_ta: Onco Targets Ther
publisher_name: Dove
keywords: MAP2K1 | furmonertinib | lung adenocarcinoma | EGFR | mutation
automl_pathway: 0.9703211
figid_alias: PMC11015836__F3
figtype: Figure
redirect_from: /figures/PMC11015836__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11015836__OTT-17-307-g0003.html
  '@type': Dataset
  description: Schematic representation of Ras/RAF/MEK/ERK signaling pathway activation
    or inhibition at different stages of treatment in our case.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - egfra
  - egf
  - celsr1a
  - rab1ab
  - braf
  - si:dkey-222f8.3
  - map2k1
  - EGF
  - RAS
  - MEK
  - BRAF Inhibitors
---
